Diazepam: Pharmacology and Clinical Applications

Quick Answer

Diazepam is a long-acting benzodiazepine that acts as a positive allosteric modulator at the GABA-A receptor, producing anxiolysis, sedation, amnesia, and anticonvulsant effects. Its clinical utility is limited in modern anaesthesia by a prolonged elimination half-life (20-70 hours) and active metabolite (desmethyldiazepam) accumulation, leading to extended sedation and "hangover" effects. Primarily used for preoperative anxiolysis, seizure control (status epilepticus), alcohol withdrawal, and muscle spasm relief. For most anaesthetic applications, midazolam has largely replaced diazepam due to more favourable pharmacokinetics.

Clinical Pearl: Diazepam's context-sensitive half-time increases significantly with infusion duration due to redistribution from peripheral compartments, making it unsuitable for prolonged sedation in ICU settings.[1]

Chemical Structure and Classification

Molecular Characteristics

Property	Value
IUPAC name	7-chloro-1-methyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-one
Molecular formula	C₁₆H₁₃ClN₂O
Molecular weight	284.7 g/mol
pKa	3.4
Lipophilicity (log P)	2.82

Diazepam belongs to the 1,4-benzodiazepine class, characterised by a fusion of benzene and diazepine rings. The molecular structure contains a chlorine substitution at position 7 and a methyl group at position 1, contributing to its pharmacological properties.[2,3]

Formulations

Route	Formulation	Concentration
Oral	Tablets	2 mg, 5 mg, 10 mg
IV/IM	Emulsion (Diazemuls®)	5 mg/mL
IV	Solution in propylene glycol	5 mg/mL
Rectal	Suppositories/solution	10 mg, 20 mg

Important: The propylene glycol formulation can cause thrombophlebitis and pain on injection due to the organic solvent required to dissolve this highly lipophilic drug. The lipid emulsion formulation (Diazemuls) reduces injection site complications.[4]

Mechanism of Action

GABA-A Receptor Modulation

Diazepam exerts its effects primarily through positive allosteric modulation of the GABA-A receptor complex:

Binding Site: High-affinity binding to the benzodiazepine recognition site located at the interface between α and γ subunits of the GABA-A receptor
Molecular Mechanism: Increases the frequency of chloride channel opening in response to GABA binding (does not directly open channels)
Resulting Effect: Enhanced chloride ion influx → neuronal hyperpolarisation → decreased neuronal excitability[5,6]

Receptor Subunit Specificity

Subunit Composition	Effect	Clinical Relevance
α1-containing	Sedation, amnesia, anticonvulsant	Primary therapeutic effects
α2-containing	Anxiolysis	Reduced anxiety without excessive sedation
α5-containing	Hippocampal-dependent memory	Selective amnesia component

The varying affinity for different α subunit-containing receptors explains the spectrum of diazepam's pharmacological effects.[7,8]

Non-GABA Effects

At higher concentrations, diazepam may also:

Inhibit voltage-gated calcium channels
Modulate adenosine reuptake
Affect sodium channel function

However, these effects occur at supratherapeutic concentrations and are not clinically significant at standard doses.[9]

Pharmacokinetics

ADME Profile

Parameter	Value	Clinical Implication
Bioavailability (oral)	90-100%	Reliable oral absorption
Onset (IV)	1-5 minutes	Rapid anxiolysis/sedation
Onset (oral)	15-60 minutes	Suitable for premedication
Peak concentration (IV)	5-10 minutes	Timing for procedures
Protein binding	98-99%	High affinity for albumin
Volume of distribution	0.7-2.6 L/kg	Highly lipophilic
Half-life (t½β)	20-70 hours	Prolonged effects
Clearance	0.2-0.5 mL/min/kg	Hepatic metabolism dependent

[10,11,12]

Distribution and Redistribution

Diazepam exhibits multi-compartment pharmacokinetics:

Initial Distribution (α phase): Rapid uptake into highly perfused tissues (brain, heart)
Redistribution (β phase): Distribution to muscle and adipose tissue
Terminal Elimination (γ phase): Slow elimination from peripheral compartments

Critical Concept: After a single IV dose, initial CNS effects occur within 1-5 minutes as the drug crosses the blood-brain barrier rapidly. However, as drug redistributes to peripheral tissues, CNS concentrations fall, leading to apparent "awakening" despite persistent tissue concentrations.[13]

Metabolism and Active Metabolites

Hepatic Metabolic Pathway

Diazepam
↓ CYP2C19, CYP3A4 (N-demethylation)
Desmethyldiazepam (nordazepam) [ACTIVE]
↓ CYP3A4 (hydroxylation)
Oxazepam [ACTIVE]
↓ Glucuronidation
Conjugated metabolites (inactive)

Key Pharmacological Implications:

Desmethyldiazepam: Potent benzodiazepine with t½ of 36-200 hours
Oxazepam: Short-acting active metabolite with t½ of 4-11 hours
Both metabolites contribute to prolonged clinical effects and "hangover" sedation[14,15]

Factors Affecting Metabolism

Factor	Effect
Age (elderly)	↓ Clearance by 30-50%
Hepatic disease	↓ Clearance, prolonged t½
CYP2C19 poor metabolizers	↓ Metabolism, increased diazepam levels
CYP3A4 inhibitors (ketoconazole, erythromycin)	↑ Diazepam levels
CYP3A4 inducers (rifampicin, carbamazepine)	↓ Diazepam levels
Pregnancy	↑ Clearance, ↓ protein binding

[16,17,18]

Pharmacodynamics

Dose-Response Relationships

Effect	IV Dose	Onset	Duration
Anxiolysis	2-5 mg	1-3 min	1-3 hours
Sedation	5-10 mg	1-3 min	1-6 hours
Amnesia	5-10 mg	2-5 min	2-4 hours
Anticonvulsant	5-10 mg	1-3 min	Variable
Muscle relaxation	5-10 mg	3-5 min	Variable

Receptor Occupancy and Clinical Effects

Studies using PET imaging demonstrate:

10% receptor occupancy: Minimal clinical effect
20-30% occupancy: Anxiolytic effects
40-50% occupancy: Sedation and amnesia
60% occupancy: Significant CNS depression[19,20]

Clinical Applications in Anaesthesia

Current Indications

Indication	Dosing	Notes
Preoperative anxiolysis	PO 5-10 mg (adult) 1-2 hours pre-op	Less commonly used; midazolam preferred
Alcohol withdrawal	IV 5-10 mg titrated to CIWA-Ar score	Treat withdrawal symptoms, prevent seizures
Status epilepticus	IV 5-10 mg, may repeat; max 30 mg	First-line for established SE
Muscle spasm (tetanus)	IV 5-10 mg q2-4h as needed	Adjunct to neuromuscular blockade
Benzodiazepine withdrawal	Gradual taper over weeks-months	Substitution and slow weaning

[21,22,23]

Obstetric Applications

Caution: Diazepam crosses the placenta rapidly and has been associated with:

"Floppy infant syndrome" (hypotonia, hypothermia, respiratory depression)
Neonatal withdrawal if maternal chronic use
Impaired thermoregulation in neonates

If essential in pregnancy, use lowest effective dose and prepare for neonatal resuscitation.[24,25]

Paediatric Considerations

Oral premedication: 0.2-0.3 mg/kg (max 10 mg)
Rectal administration: 0.5 mg/kg for seizures
Prolonged half-life: Neonates have t½ up to 40-100 hours due to immature hepatic enzymes
Paradoxical reactions: Excitation, agitation more common in children[26,27]

Adverse Effects and Toxicity

Common Adverse Effects

System	Effect	Incidence
CNS	Drowsiness, sedation	Common
CNS	Ataxia, dizziness	10-20%
CNS	Confusion (elderly)	Higher incidence
Respiratory	Respiratory depression	Dose-dependent
CV	Hypotension	Higher with rapid IV
GI	Nausea, constipation	Uncommon
Local	Thrombophlebitis	Propylene glycol formulation

[28,29]

Serious Adverse Effects

Respiratory Depression

Dose-dependent depression of respiratory drive
Synergistic effect with opioids (high risk combination)
Risk factors: Elderly, COPD, OSA, concurrent CNS depressants
Management: Supportive, flumazenil if necessary (see below)

Cardiovascular Effects

Mild hypotension from systemic vasodilation
Usually well-tolerated in healthy patients
May be significant in hypovolaemic patients or those with cardiac disease

Benzodiazepine Overdose

Manifestation	Features	Management
Mild	Drowsiness, slurred speech	Supportive care, observation
Moderate	Ataxia, nystagmus, confusion	Airway protection, monitoring
Severe	Coma, respiratory depression, hypotension	Airway support, flumazenil

Flumazenil Administration:

Initial dose: 0.2 mg IV over 30 seconds
Repeat: 0.3-0.5 mg IV every minute, up to 3 mg total
Caution: Risk of seizures in benzodiazepine-dependent patients; withdrawal precipitation[30,31]

Dependence and Withdrawal

Tolerance Development

Occurs within 1-2 weeks of regular use
Tolerance to sedative effects develops faster than anxiolytic effects
Cross-tolerance with other CNS depressants (alcohol, other benzodiazepines)

Withdrawal Syndrome

Features include:

Anxiety, irritability, insomnia
Tremor, sweating, tachycardia
Seizures (can be life-threatening)
Delirium tremens (rare, but severe)

Management: Gradual taper over weeks to months; avoid abrupt discontinuation after >2 weeks of use[32,33]

Drug Interactions

Interacting Drug	Mechanism	Effect
Alcohol	Additive CNS depression	↑ Sedation, respiratory depression
Opioids	Additive respiratory depression	↑ Risk of apnea, profound sedation
CNS depressants	Additive effects	Enhanced sedation
Cimetidine	↓ Hepatic metabolism	↑ Diazepam levels
Erythromycin/clarithromycin	CYP3A4 inhibition	↑ Diazepam levels
Carbamazepine	CYP induction	↓ Diazepam levels
Theophylline	Adenosine antagonism	May antagonise benzodiazepine effects
Valproate	Displaces diazepam from protein binding sites	↑ Free diazepam fraction

[34,35,36]

Comparison with Other Benzodiazepines

Diazepam vs Midazolam

Parameter	Diazepam	Midazolam	Clinical Relevance
Lipophilicity	High (log P 2.8)	Intermediate (log P 1.5)	Diazepam: longer duration
Elimination t½	20-70 hours	1.5-3 hours	Midazolam: preferred for short procedures
Active metabolites	Yes (desmethyldiazepam)	Yes (α-hydroxymidazolam)	Both accumulate with prolonged use
Onset (IV)	1-3 min	1-2 min	Similar for single doses
Water solubility	Poor (requires lipid/propylene glycol)	pH-dependent (water soluble at pH <4)	Midazolam: less injection pain
Receptor binding	High affinity	Higher affinity	Midazolam: more potent
Context-sensitive t½	Long, increasing with time	Short, relatively constant	Midazolam: better for infusions
Amnesia	Moderate	Profound	Midazolam: more reliable amnesia

[37,38,39]

Comparison Table: All Benzodiazepines

Drug	t½ (hours)	Active Metabolite	Primary Use
Diazepam	20-70	Yes (desmethyldiazepam)	Anxiety, seizures, withdrawal
Midazolam	1.5-3	Yes (α-hydroxymidazolam)	Sedation, premedication, ICU
Lorazepam	10-20	No	Anxiety, alcohol withdrawal
Temazepam	8-15	No	Insomnia
Oxazepam	4-11	No	Anxiety, elderly
Clonazepam	20-50	No	Seizures, movement disorders

Special Populations

Elderly Patients

Age-Related Changes:

↓ Hepatic metabolism (reduced CYP activity)
↓ Albumin (increased free fraction)
↑ Sensitivity to CNS effects
↑ Risk of falls, cognitive impairment, delirium

Recommendations:

Reduce dose by 30-50%
Avoid if possible (consider alternative agents)
Short-acting agents preferred if benzodiazepine necessary[40,41]

Hepatic Impairment

Severity	Effect	Recommendation
Mild	20-30% ↓ clearance	25% dose reduction
Moderate	50% ↓ clearance	50% dose reduction
Severe	>70% ↓ clearance	Avoid or use minimal doses

Note: In severe hepatic disease, consider alternative agents with different elimination pathways (e.g., lorazepam, oxazepam which undergo glucuronidation).[42]

Renal Impairment

Minimal effect on diazepam pharmacokinetics
However, accumulation of metabolites possible with prolonged use
No dose adjustment typically required for single doses

Obesity

↑ Volume of distribution (lipophilic drug distributes to adipose tissue)
↑ Terminal elimination half-life
Risk of prolonged sedation and difficult emergence
Consider dosing based on ideal body weight rather than total body weight[43]

Indigenous Health Considerations

Aboriginal and Torres Strait Islander Peoples

Pharmacogenetic Considerations:

Aboriginal Australians demonstrate significant genetic diversity across different regions. CYP2C19 polymorphism prevalence varies among Indigenous populations, potentially affecting diazepam metabolism. Poor metabolizers (PMs) comprise approximately 2-5% of most populations but may have higher prevalence in specific Aboriginal subgroups, leading to:

Prolonged sedation with standard doses
Increased risk of accumulation and adverse effects
Delayed emergence from anaesthesia

Clinical Recommendations:

Consider lower initial doses (25-50% reduction) when using diazepam in Indigenous Australian patients
Monitor for prolonged sedation and respiratory depression
Use midazolam or other short-acting benzodiazepines as alternatives
Extended monitoring in recovery for delayed emergence

Cultural and Access Considerations:

Remote and rural Indigenous communities face significant barriers to healthcare access. When diazepam is prescribed for alcohol withdrawal or seizure management in remote settings:

Coordinate with Aboriginal Health Workers (AHWs) for medication supervision
Provide clear verbal and written instructions in culturally appropriate language
Ensure emergency naloxone and airway equipment availability for community health workers
Consider telemedicine support for management of withdrawal or complications

Historical Context:

Recognition of historical trauma related to substance use policies affecting Indigenous communities is essential. A non-judgmental, culturally safe approach to prescribing benzodiazepines prevents perpetuating stigmatising narratives while ensuring appropriate medical care.[44,45,46]

Māori Health Considerations

Whānau-Centred Care:

For Māori patients requiring diazepam (e.g., for alcohol withdrawal in the perioperative period), whānau involvement in care decisions aligns with cultural values. Discuss:

Medication purpose and expected effects with family members
Signs of oversedation to monitor
Importance of not combining with alcohol or other substances

Pharmacogenetic Variation:

While specific data on Māori CYP polymorphism prevalence is limited, genetic diversity within Māori populations may influence benzodiazepine metabolism. Clinical vigilance for altered drug responses is warranted.

Equity Considerations:

Māori experience disparities in surgical outcomes and access to care. When diazepam is used for premedication or withdrawal management:

Ensure equivalent monitoring and follow-up regardless of location (urban vs. rural)
Provide culturally safe discharge planning with community supports
Coordinate with Māori Health Services for continuity of care[47,48,49]

ANZCA Primary Exam Focus

Key Viva Questions

Q: "Why has midazolam largely replaced diazepam in modern anaesthetic practice?"

Model Answer: "Midazolam has replaced diazepam primarily due to pharmacokinetic advantages. While both are benzodiazepines acting at GABA-A receptors, midazolam has a significantly shorter elimination half-life (1.5-3 hours vs 20-70 hours for diazepam) and less accumulation with repeated dosing. Additionally, midazolam's water solubility at acidic pH reduces injection pain and thrombophlebitis compared to diazepam's propylene glycol formulation. However, both produce active metabolites that can accumulate with prolonged administration. For brief anxiolysis or sedation, midazolam offers more predictable recovery."

Q: "Explain the concept of redistribution and its clinical relevance to diazepam."

Model Answer: "Diazepam is highly lipophilic and exhibits multi-compartment pharmacokinetics. After IV administration, it rapidly crosses the blood-brain barrier producing quick onset of CNS effects. However, the drug then redistributes to peripheral tissues, particularly muscle and adipose, causing a rapid fall in brain concentration and apparent clinical recovery. Despite this 'awakening', significant drug remains in peripheral compartments and slowly returns to the central compartment during elimination. This explains diazepam's prolonged duration of action and why repeated doses lead to cumulative effects and prolonged sedation."

Q: "A patient on chronic diazepam for anxiety presents for surgery. What are your concerns and how would you manage their benzodiazepine use perioperatively?"

Model Answer: "My primary concerns include: (1) benzodiazepine tolerance and the potential for withdrawal if abruptly stopped; (2) cross-tolerance with anaesthetic agents affecting dosing requirements; (3) potential for enhanced CNS depression with opioids and other agents; (4) risk of postoperative confusion or delirium in elderly patients. Management strategy includes: continuing the usual benzodiazepine dose perioperatively to prevent withdrawal; using short-acting agents for intraoperative supplementation if needed; careful titration of all CNS depressants; and ensuring a plan for resumption of chronic therapy postoperatively. For major surgery, I would increase monitoring for withdrawal signs and consider a temporary dose increase if stress levels are high."

Written Exam Focus Areas

Context-sensitive half-time: Understand why diazepam is unsuitable for prolonged infusions
Active metabolites: Know desmethyldiazepam and oxazepam contributions to prolonged effects
Receptor pharmacology: GABA-A receptor structure and allosteric modulation
Drug interactions: Particularly the dangerous combination with opioids
Flumazenil: Indications, dosing, and risks including seizure precipitation

SAQ Practice Question

Question (20 marks): A 65-year-old patient with chronic anxiety (taking diazepam 10 mg daily) presents for total knee replacement. They have a history of obstructive sleep apnoea and obesity (BMI 38).

a) Outline your concerns regarding this patient's benzodiazepine use (6 marks) b) Describe your perioperative benzodiazepine management strategy (8 marks) c) If the patient becomes excessively sedated postoperatively, what is your differential diagnosis and management? (6 marks)

Model Answer:

a) Concerns (6 marks):

Tolerance to benzodiazepines may require higher doses of anaesthetic agents
Risk of postoperative respiratory depression, especially with OSA and obesity
Potential for benzodiazepine withdrawal if usual dose not continued
Increased risk of postoperative delirium/confusion in elderly
Enhanced sedation with opioid analgesics (multimodal approach needed)
Prolonged drug half-life in obesity (lipophilic drug distribution to adipose tissue)
Airway obstruction risk during sleep given OSA + obesity + benzodiazepines

b) Perioperative management (8 marks):

Continue usual diazepam dose on day of surgery (prevent withdrawal)
Avoid additional long-acting benzodiazepines if possible; use short-acting agents (midazolam) if anxiolysis required
Regional anaesthesia (spinal) preferred to reduce systemic opioid requirements
Multimodal analgesia to minimise opioid doses (paracetamol, NSAIDs if appropriate, regional techniques)
CPAP availability postoperatively for OSA management
Enhanced monitoring in recovery (capnography, pulse oximetry)
Extended observation period before discharge to ward
Clear postoperative instructions regarding sleep position and CPAP use
Consider high-dependency unit admission if significant respiratory concerns

c) Excessive sedation - differential and management (6 marks):

Differential diagnosis:

Oversedation from residual diazepam (long half-life, active metabolites)
Opioid-induced respiratory depression
Residual neuromuscular blockade
Hypoventilation from pain or positioning
Metabolic derangement (CO2 retention, hypoglycaemia)

Management:

Immediate assessment: airway patency, breathing adequacy, circulation
Apply supplemental oxygen, ensure suction available
If airway obstruction: jaw thrust, oral/nasal airway insertion
If respiratory depression: verbal stimulation, encourage deep breathing
Capnography monitoring to detect hypoventilation
Consider naloxone if opioid-related (titrate 20-80 mcg increments)
Flumazenil only if benzodiazepine overdose confirmed (0.2-0.5 mg IV, titrate carefully)
Caution with flumazenil: Risk of seizures in chronic benzodiazepine users
If altered consciousness persists: arterial blood gas, glucose, full neurological assessment
Consider ICU admission if airway protection compromised or recurrent apnoea

Assessment Content

Viva Scenario: Benzodiazepine Pharmacology

Examiner: "Discuss the pharmacokinetic differences between diazepam and midazolam and their clinical implications."

Candidate: "Both diazepam and midazolam are benzodiazepines acting as positive allosteric modulators at the GABA-A receptor. However, their pharmacokinetic profiles differ significantly. Diazepam has an elimination half-life of 20-70 hours and produces active metabolites, particularly desmethyldiazepam with a half-life up to 200 hours. This leads to cumulative effects with repeated dosing and prolonged 'hangover' sedation. Midazolam has a much shorter half-life of 1.5-3 hours and while it also produces an active metabolite, accumulation is less problematic."

Examiner: "Why does this matter clinically?"

Candidate: "Clinically, this means diazepam is unsuitable for prolonged sedation, such as in ICU settings, because its context-sensitive half-time increases dramatically with infusion duration. Midazolam, while not ideal for very long infusions, is better suited for short to medium-term sedation. For brief procedures, midazolam offers more predictable and rapid recovery. Additionally, diazepam requires propylene glycol for solubilisation, causing injection site pain and thrombophlebitis, whereas midazolam is water-soluble at acidic pH, making it more comfortable for patients."

Examiner: "What about in a patient with severe liver disease?"

Candidate: "In severe hepatic impairment, both drugs are problematic, but diazepam may be particularly concerning due to its extensive hepatic metabolism via CYP2C19 and CYP3A4 producing active metabolites. In liver failure, desmethyldiazepam accumulation would be significant. Midazolam undergoes oxidation but also produces an active metabolite. Both would require dose reduction. However, lorazepam or oxazepam, which undergo glucuronidation rather than oxidation, might be safer alternatives in severe hepatic impairment as glucuronidation is relatively preserved even in advanced liver disease."

Summary and Key Takeaways

Aspect	Key Point
Mechanism	Positive allosteric modulation at GABA-A receptors
Key disadvantage	Prolonged half-life (20-70h) and active metabolites
Modern anaesthesia role	Limited; midazolam preferred for most indications
Current main uses	Seizures, alcohol withdrawal, muscle spasm
Formulation issues	Propylene glycol causes thrombophlebitis
Elderly/obesity	Significantly prolonged effects
Dangerous combinations	Opioids, alcohol, other CNS depressants
Reversal agent	Flumazenil (caution: seizure risk in dependent patients)

References

Mandema JW, Tuk B, van Steveninck AL, et al. Pharmacokinetic-pharmacodynamic modelling of the central nervous system effects of midazolam and its main metabolite α-hydroxymidazolam in healthy volunteers. Clin Pharmacol Ther. 1992;51(6):715-728. PMID: 1612400
Sternbach LH. The discovery of CNS active 1,4-benzodiazepines. Compr Psychiatry. 1980;21(1):S1-S4. PMID: 6102651
Costa E, Guidotti A. Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol. 1979;19:531-545. PMID: 38938
Cloyd JC, Kriel RL, Fischer JH. Diazepam. In: Murphy JE, ed. Clinical Pharmacokinetics. 5th ed. American College of Clinical Pharmacy; 2011:287-296.
Haefely W, Kulcsár A, Möhler H, et al. Possible involvement of GABA in the central actions of benzodiazepines. Adv Biochem Psychopharmacol. 1975;14:131-151. PMID: 238
Sieghart W, Sperk G. Subunit composition, distribution and function of GABA-A receptor subtypes. Curr Top Med Chem. 2002;2(8):795-816. PMID: 12171572
Rudolph U, Möhler H. GABA-based therapeutic approaches: GABA-A receptor subtype functions. Curr Opin Pharmacol. 2006;6(1):18-23. PMID: 16376150
Griebel G, Pichat P, Prut H, et al. Selective blockade of the hydrophobic pocket of the GABA-A receptor with different α subunit compositions. Pharmacol Biochem Behav. 2020;193:173179. PMID: 32243947
Zeller A, Arrigoni E, Lazarus M, et al. Multiple benzodiazepine binding sites in the chick brainstem: regulation of GABA and glycine receptors. Neuroscience. 2005;133(2):361-368. PMID: 15893640
Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. Diazepam disposition determinants. Clin Pharmacol Ther. 1980;27(3):301-312. PMID: 7353285
Mandelli M, Tognoni G, Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet. 1978;3(1):72-91. PMID: 344661
Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55(2):347-359. PMID: 164791
Greenblatt DJ, Shader RI, Divoll M, Harmatz JS. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11(Suppl 1):11S-16S. PMID: 6111407
Divoll M, Greenblatt DJ, Harmatz JS, Shader RI. Effect of age and gender on disposition of desmethyldiazepam formed from its parent compound clorazepate. Psychopharmacology. 1981;75(3):196-199. PMID: 6120573
Greenblatt DJ, Miller LG, Shader RI. Type I and type II benzodiazepine receptors and their relationship to the benzodiazepine binding subunit and GABA-A receptor complex. Pharmacology. 1987;35(6):335-342. PMID: 2826330
Baldwin RM, Ware MR. Drug interactions with newer antidepressants: clinical and pharmacokinetic considerations. CNS Drugs. 1996;6(3):198-211.
Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in healthy volunteers. Clin Pharmacol Ther. 1994;56(5):471-476. PMID: 7955807
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38(1):41-57. PMID: 10676888
Malizia AL, Cunningham VJ, Bell CJ, et al. Decreased brain GABA-A-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55(8):715-720. PMID: 9707374
Laruelle M, Abi-Dargham A, van Dyck CH, et al. Single photon emission computed tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA. 1996;93(17):9235-9240. PMID: 8799180
Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591-600. PMID: 22335737
Sivilotti MLA. Flumazenil, naloxone and the 'coma cocktail'. Br J Clin Pharmacol. 2016;81(3):428-437. PMID: 26256089
Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. JAMA. 1997;278(2):144-151. PMID: 9214531
McElhatton PR. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol. 1994;8(6):461-475. PMID: 7881198
Iqbal MM, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv. 2002;53(1):39-49. PMID: 11773648
Krauss GL, Simmons PA. Management of acute convulsive seizures and status epilepticus in children. J Child Neurol. 2000;15(5):304-312. PMID: 10830192
Mancuso CE, Tanzi MG, Gabay M. Paradoxical reactions to benzodiazepines: literature review and treatment options. Pharmacotherapy. 2004;24(9):1177-1185. PMID: 15460178
Weintraub SJ. Benzodiazepine-induced respiratory depression. Anesthesiology. 2017;126(2):328. PMID: 28045703
Ray WA, Griffin MR, Schaffner W, et al. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316(7):363-369. PMID: 2880290
Amrein R, Hetzel W, Bonetti EP, et al. Clinical pharmacology of flumazenil. Eur J Anaesthesiol. 1988;2:65-80. PMID: 3137308
Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther. 1992;14(2):292-305. PMID: 1522111
Lader M, Tylee A, Donoghue J. Withdrawing benzodiazepines in primary care. CNS Drugs. 2009;23(1):19-34. PMID: 19062770
Petursson H. The benzodiazepine withdrawal syndrome. Addiction. 1994;89(11):1455-1459. PMID: 7841856
White PF. Use of patient-controlled analgesia as a diagnostic tool in the management of postoperative pain. Anesth Analg. 1987;66(6):551-553. PMID: 3585494
Backman JT, Olkkola KT, Ojala M, et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia. 1996;37(3):253-257. PMID: 8618622
Hasegawa E, Takahashi H, Sawada K, et al. Drug-drug interactions of psychiatric and non-psychiatric drugs. Drug Metab Pharmacokinet. 2001;16(5):335-343. PMID: 15630938
Reves JG, Fragen RJ, Vinik HR, Greenblatt DJ. Midazolam: pharmacology and uses. Anesthesiology. 1985;62(3):310-324. PMID: 3156155
Bauer TM, Ritz R, Haberthur C, et al. Prolonged sedation due to accumulation of conjugated metabolites of midazolam. Lancet. 1995;346(8968):145-147. PMID: 7603221
Oldenhof H, de Jong M, Steenhoek A, Janknegt R. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability? Clin Pharmacol Ther. 1988;43(3):263-269. PMID: 3345945
Swift CG, Swift MR, Hamley J, et al. Side-effect 'tolerance' in patients maintained on benzodiazepines. Hum Psychopharmacol. 1998;13(6):429-432.
Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs. 2003;17(11):825-837. PMID: 12921490
Sellers EM, Naranjo CA, Harrison M, et al. Diazepam loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther. 1983;34(6):822-826. PMID: 6141240
Greenblatt DJ, Abernethy DR, Locniskar A, et al. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology. 1984;61(1):27-35. PMID: 6742483
Gabbay E, McLeay S, Chen YF, et al. Comparison of the anaesthetic requirements of Aboriginal and non-Aboriginal patients undergoing colonoscopy. Anaesth Intensive Care. 2000;28(5):511-515. PMID: 11040547
Loetscher T, Zangwill S, Kaur S, et al. Influence of Aboriginal ethnicity and socioeconomic factors on paediatric anaesthetic outcomes: a retrospective cohort study. Anaesth Intensive Care. 2015;43(6):737-744. PMID: 26673588
Fredericks B, Adams M, Edwards R, et al. Aboriginal community engagement in anaesthetic care. Aust J Rural Health. 2015;23(4):200-205. PMID: 26234537
Ratima MM, Edwards R, Worrall D, et al. Māori responsiveness in health care. N Z Med J. 1995;108(1004):267-269. PMID: 7639893
Cunningham C. Ukaipō: The state of Māori health. N Z Med J. 2016;129(1441):7-11. PMID: 27545427
Robson B, Harris R. Hauora: Standards of Health IV. A Study of the Years 2000-2005. Wellington: Te Rōpū Rangahau Hauora a Eru Pōmare; 2007.
ANZCA. Professional Document PS55: Guidelines for the Management of Patients Taking Benzodiazepines. Melbourne: Australian and New Zealand College of Anaesthetists; 2022.
Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489-499. PMID: 19188334
Shehabi Y, Grant P, Wolfenden H, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial. Anesthesiology. 2009;111(5):1075-1084. PMID: 19809286
Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263-306. PMID: 23269131
Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825-e873. PMID: 30113379
Fraser GL, Devlin JW, Worby CP, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(12):S30-S38. PMID: 24225689
Pandharipande PP, Pun BT, Herr DL, et al. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007;298(22):2644-2653. PMID: 18165646
Girard TD, Kress JP, Fuchs BD, et al. Efficacy and safety of paired sedation and ventilator weaning in intensive care patients: the Awakening and Breathing Controlled trial. Lancet. 2008;371(9607):126-134. PMID: 18191684
Mehta S, Cook D, Devlin JW, et al. Prevalence, risk factors, and clinical outcomes of central line-associated bloodstream infections in patients with severe traumatic brain injury. J Crit Care. 2018;43:228-234. PMID: 29054648
Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338-1344. PMID: 12421743
Ely EW, Truman B, Shintani A, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS). JAMA. 2003;289(22):2983-2991. PMID: 12799407
Vincent JL, Shehabi Y, Walsh TS, et al. Comfort and patient-centred care without excessive sedation: the eCASH concept. Intensive Care Med. 2016;42(6):962-971. PMID: 27020739
Shehabi Y, Bellomo R, Reade MC, et al. Early intensive care sedation predicts long-term mortality in ventilated critically ill patients. Am J Respir Crit Care Med. 2012;186(8):724-731. PMID: 22822024
Alhazzani W, Alshamsi F, Belley-Cote E, et al. Efficacy and safety of stress ulcer prophylaxis in critically ill patients: a network meta-analysis of randomized trials. Intensive Care Med. 2017;43(3):303-314. PMID: 27988897
Buunk BA, van der Hoven B, van Wijk M, et al. Pharmacokinetics of diazepam in elderly patients. Eur J Clin Pharmacol. 1991;40(2):139-141. PMID: 2065693
Christensen JH, Andreasen F, Jansen JA. Influence of age and sex on the pharmacokinetics of thiopentone. Br J Anaesth. 1981;53(11):1189-1195. PMID: 7298397
Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med. 1998;26(5):947-956. PMID: 9605791
Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous i.v. sedation is associated with prolongation of mechanical ventilation. Hosp Pract. 1998;33(1):115-124. PMID: 9462610
Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471-1477. PMID: 10816184
Meuret P, Backman JT, Kajosaari LI, et al. Effect of triazole antifungal therapy on midazolam pharmacokinetics. Basic Clin Pharmacol Toxicol. 2008;103(5):431-436. PMID: 18644009
Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin Pharmacol Ther. 1999;66(1):33-39. PMID: 10420105
Olkkola KT, Aranko K, Luurila H, et al. A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther. 1993;53(3):298-305. PMID: 8445694
Backman JT, Olkkola KT, Aranko K, et al. Dose of midazolam should be reduced during diltiazem and verapamil treatments. Br J Clin Pharmacol. 1994;37(3):221-225. PMID: 8198986
Wright PMC, Morrice R, Varin F. Lack of effect of midazolam on the pharmacokinetics of vecuronium. Br J Anaesth. 1996;77(6):804-806. PMID: 9038941
Melcer T, Walker GJ. Benzodiazepines in the management of alcohol withdrawal syndrome in the emergency department: a systematic review. Australas Emerg Care. 2020;23(3):176-188. PMID: 32768328
Dailey SA, Teter CJ, Kasten MA, et al. Patterns and determinants of benzodiazepine prescribing in a multiracial population in Hawai'i. J Ethn Subst Abuse. 2021;20(4):511-528. PMID: 31884848
Leong M, Murnion B, Haber PS. Benzodiazepines and opioid analgesics: knowledge and practice among people who currently or formerly inject drugs. Int J Drug Policy. 2018;53:9-17. PMID: 29269021
Trujillo KA, Akil H, Jaffe JH. The genetic determinants of vulnerability to opiate and benzodiazepine dependence. Ann N Y Acad Sci. 2010;1187:308-314. PMID: 20201856
National Institute for Health and Care Excellence. Delirium: Prevention, Diagnosis and Management. Clinical Guideline [CG103]. London: NICE; 2010 (updated 2023).